ALTIMMUNE, INC.

ALT · NASDAQ

Pharmaceutical Preparation Manufacturing

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

ESG Scores

Overall ESG

4.3

Environmental

5.4

Social

3.6

Governance

5.4

Gender Diversity

Female Directors0.22219999999999998%

Women in Workforce0.532%

CEO GenderMale

Market Data

Price$3.56+0.06 (+1.71%)

Market Cap$463M

P/E Ratio—

EPS$—

52W High$7.73

52W Low$2.87

Beta0.37